General MedicationsORALGeneric
RITONAVIR
RITONAVIR
Standard Dose
50MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: None (Tentative Approval)
Summary
Approval overview RITONAVIR is listed in Drugs@FDA under application 205040 (NDA).
Review priority: PRIORITY Marketing status: None (Tentative Approval) Active ingredient RITONAVIR Form and strength TABLET; ORAL - 50MG Sponsor CIPLA LIMITED Submission history Latest submission status date: 2015-03-29 00:00:00.
Structured Monograph
Clinical summary
Approval overview RITONAVIR is listed in Drugs@FDA under application 205040 (NDA). Review priority: PRIORITY Marketing status: None (Tentative Approval) Active ingredient RITONAVIR Form and strength TABLET; ORAL - 50MG Sponsor CIPLA LIMITED Submission history Latest submission status date: 2015-03-29 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: None (Tentative Approval)
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.